Unlocking glioma vulnerabilities: targeting regulated cell death pathways for innovative therapies - PubMed

3 months ago

Glioma is the most prevalent primary brain tumor, originating from glial cells or their progenitors.
Gliomas are classified into astrocytomas, oligodendrogliomas, and ependymomas based on histology.
Gliomas exhibit high recurrence rates and poor clinical outcomes due to their invasive nature and resistance to chemotherapy.
Regulated cell death (RCD) plays a dual role in cancer: preventing tumorigenesis under normal conditions and being evaded by tumor cells in pathological conditions.
Different RCD pathways can influence the tumor immune microenvironment, affecting therapeutic outcomes.
Targeting RCD mechanisms is a promising strategy to overcome therapeutic resistance and improve glioma immunotherapies.
Key RCD pathways in glioma include pyroptosis, ferroptosis, necroptosis, and autophagy, each playing critical roles in tumor progression.
Therapeutic strategies targeting RCD include GPX4 inhibitors, oncolytic virotherapy, and emerging agents.
Nanoparticle-based drug delivery systems and multi-omics approaches are being explored to optimize personalized combination therapies for glioma.

Hasty Briefsbeta